PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
01-Sep-2022 Advanced Wound Management Market Size, Top Leading Manufacturers with Share 2031 MARKITWIRED
01-Sep-2022 InfanDx AG Appoints Nicole Witzmann as Chief Financial Officer InfanDx AG
01-Sep-2022 BIOCORP: Its Range of Connected Devices Featured at Several International Conferences and Exhibitions Businesswire
01-Sep-2022 EUROAPI: Availability of 2022 Half-Year Financial Report Businesswire
01-Sep-2022 EUROAPI: Solid Business and Financial Performance in H1-2022 - Net Sales and Core EBITDA Margin Guidance for 2022 Confirmed Businesswire
01-Sep-2022 Cerveau Technologies Inc. and Alnylam® Pharmaceuticals Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research Businesswire
01-Sep-2022 ProtonDx’s Dragonfly Diagnostic System Successfully Deployed at the 2022 Commonwealth Games ProtonDx
01-Sep-2022 Laser Therapy Devices Market reach a value of almost US$ 2 billion by 2022 MARKITWIRED
01-Sep-2022 Herbal Medicinal Products Market is expected to reach US$ 360.35 Billion by the end of 2031 | FMI MARKITWIRED
01-Sep-2022 Vascular Closure Device (VCD) Market will reach US$ 963 million value towards the end of 2022 MARKITWIRED
01-Sep-2022 Microscope Digital Cameras Market to reach a value of around US$ 1.2 Billion by the end of 2027 MARKITWIRED
01-Sep-2022 PharmaSGP reports record revenues (+59%) and record earnings (+86%) in the first half of 2022 PharmaSGP Holding SE
01-Sep-2022 APONTIS PHARMA: SECURE study and START study add-on analysis confirm superior efficacy of Single Pill APONTIS PHARMA AG
01-Sep-2022 Zur Rose Group successfully completes placement of approx. CHF 95 million Convertible Bonds and the approx. CHF 44 million Capital Increase by way of an accelerated book building process Zur Rose Group AG
31-Aug-2022 MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters MorphoSys AG
31-Aug-2022 Zur Rose Group launches approx. CHF 100 million Convertible Bonds and approx. CHF 50 million Capital Increase by way of an accelerated book building process Zur Rose Group AG
31-Aug-2022 BOC Sciences Yields Peptide-siRNA Conjugates of High Quality BOC Sciences
31-Aug-2022 EpiEndo Commences LPS Challenge Trial for Lead Candidate EP395 B3C newswire
31-Aug-2022 BOC Sciences Developed Strain Expression Systems to Enhance Fermentation Productivity BOC Sciences
31-Aug-2022 Creative Peptides Released One-Stop Solution for All Peptide Drug Conjugate Needs Creative Peptides